版本:
中国

BRIEF-Roche CEO says Aphinity study impact on Perjeta sales not seen until 2018

April 27 Roche Holding Ag's

* CEO Severin Schwan says Ocrevus launch off to a very good start

* Roche expects competition from Rituxan biosimilars in second quarter, Herceptin biosimilars in the second half

* Drug chief Dan O'Day says remains confident with the totality of our portfolio that we can offset the introduction of biosimilars

* Schwan says aphinity study's impact on perjeta sales not seen until 2018 Source text for Eikon: Further company coverage: (Reporting by John Miller)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐